Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 placebo-controlled trial of teprotumumab in Japanese adults with chronic inactive thyroid eye disease
jRCT2031220730Phase 3Active, not recruiting
- Sponsor
- Horizon Therapeutics
- Start
- Mar 2023
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in Graves Orbitopathy (GO) comparing Teprotumumab with Placebo (2 arms). Primary endpoints: Mean change from baseline in proptosis at Week 24 and Proptosis responder rate at Week 24. Started Mar 2023; status: active, not recruiting.
02
Drugs
teprotumumab
03
Conditions
Graves Orbitopathy (GO)
Beyond the preview
Go deeper on jRCT2031220730.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031220730.